Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Bach‐Yen Nguyen et al.|The Lancet HIV|2018Cited by 145
Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized micePhilip Arandjelovic, Marc Pellegrini, Youry Kim et al.|Cell Reports Medicine|2023Cited by 40
Memory CD4+ T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latencyThomas A. Rasmussen, Sharon R. Lewin, Jennifer M. Zerbato et al.|Cell Reports Medicine|2022Cited by 38
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Christine Katlama, Jean‐Michel Molina et al.|The Lancet HIV|2023Cited by 31
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controlsJames McMahon, Sharon R. Lewin, Jennifer M. Zerbato et al.|EBioMedicine|2021Cited by 21